Refractory anemia with excess blasts in transformation
MONDO:0015692Refractory anemia with excess blasts in transformation (RAEB-T) is characterized by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood. The peripheral blood blast count ranges from 20% to 30%. RAEB-T used to be a subcategory of myelodysplastic syndromes in the past. Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes. The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%. The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments. Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome). A minority of cases are part of RAEB-2.
Also known as: RAEB-T, RAEB-t
1868 clinical trials for this condition and its sub-types, 6 tagged with Refractory anemia with excess blasts in transformation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug combo aims to control rare blood cancer in High-Risk patients
Disease control Recruiting nowThis study tests a combination of two drugs, azacitidine and enasidenib, in people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if the drugs can stop cancer growth and improve outcomes. …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Gene test may help prevent deadly fungal infections in leukemia patients
Disease control Recruiting nowThis study tests whether a genetic test can help decide which leukemia patients need a strong antifungal drug (posaconazole) to prevent serious mold infections during chemotherapy. About 410 adults with acute myeloid leukemia will be randomly assigned to receive the drug or a pla…
Sponsor: Bochud Pierre-Yves • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC